|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Maastricht University Medical Center DSM Nutritional Products, Inc. |
|---|---|
| Information provided by: | Maastricht University Medical Center |
| ClinicalTrials.gov Identifier: | NCT00867555 |
Purpose
The body of evidence regarding the health benefits of green tea has grown considerably during the last decade and includes antioxidant properties, anti- cancer, anti-obesity and anti-diabetes effects. There has been evidence that green tea extract favorably affect body weight and body fat and has positive effects on blood glucose control
Aim of this study is to investigate the short term effect (3-day)of TEAVIGO (high in the catechin EGCG) on postprandial fat oxidation during different phases of the postprandial period in overweight subjects. Secondly, in a subset of volunteers changes in lipolysis and glucose metabolism will be studied in skeletal muscle and adipose tissue.
| Condition | Intervention |
|---|---|
|
Obesity Type 2 Diabetes Mellitus |
Dietary Supplement: Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study |
| Official Title: | Effects of the Green Tea Extract TEAVIGO High in EGCG, on Postprandial Fat Oxidation in Overweight Volunteers |
| Estimated Enrollment: | 24 |
| Study Start Date: | October 2008 |
| Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
EGCG: Experimental
Double blind randomized, placebo-controlled cross-over design with two arms:
|
Dietary Supplement: Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation
green tea extract TEAVIGO, high in EGCG
|
| placebo: Placebo Comparator |
Dietary Supplement: Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation
green tea extract TEAVIGO, high in EGCG
|
Eligibility| Ages Eligible for Study: | 20 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Judith Can, Drs | +31433884256 | J.vanCan@Hb.unimaas.nl |
| Netherlands | |
| Dept Human Biology, Maastricht University | Recruiting |
| Maastricht, Netherlands, 6200 MD | |
| Contact: Judith Can, Bsc J.vanCan@Hb.unimaas.nl | |
| Principal Investigator: Ellen E Blaak, PhD, Prof | |
| Principal Investigator: | Ellen E Blaak, PhD, Prof | Maastricht University Medical Center |
More Information
| Responsible Party: | Maastricht University ( Ellen E Blaak, Prof ) |
| Study ID Numbers: | MEC 08-3-052 |
| Study First Received: | March 23, 2009 |
| Last Updated: | March 23, 2009 |
| ClinicalTrials.gov Identifier: | NCT00867555 History of Changes |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
|
Anticarcinogenic Agents Epigallocatechin gallate Obesity Antioxidants Metabolic Diseases Diabetes Mellitus Endocrine System Diseases Overweight Epigallocatechin Neuroprotective Agents |
Body Weight Signs and Symptoms Tea Diabetes Mellitus, Type 2 Nutrition Disorders Overnutrition Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder |
|
Anticarcinogenic Agents Obesity Epigallocatechin gallate Metabolic Diseases Antioxidants Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Antimutagenic Agents Diabetes Mellitus Endocrine System Diseases Overweight |
Neuroprotective Agents Protective Agents Pharmacologic Actions Body Weight Signs and Symptoms Therapeutic Uses Diabetes Mellitus, Type 2 Nutrition Disorders Overnutrition Glucose Metabolism Disorders Central Nervous System Agents |
